Thus, specific targeting of VEGFR3 signaling to improve lymphatic function either by ligand (VEGF-C/D) overexpression or by controlling chronic inflammation with lymphatic dysfunction related obesity and additional metabolic disorders. The gene discussed is VEGFC; the disease is obesity disorder.